Dyckerhoff Stefan A 4

What Happened

• Stefan A. Dyckerhoff, a director of Astera Labs, sold 12,499 shares in six open‑market transactions on May 7, 2026. Transactions: 1,783 shares @ $199.00 ($354,817); 4,238 @ $199.00 ($843,362); 336 @ $199.00 ($66,864); 1,722 @ $201.10 ($346,298); 4,095 @ $201.10 (weighted avg; see note) ($823,513); 325 @ $201.10 ($65,358). Total proceeds ≈ $2,500,212. These sales were made pursuant to a Rule 10b5‑1 trading plan adopted December 1, 2025. This filing reports sales (not purchases).

Key Details

• Transaction date: May 7, 2026; Form 4 filed: May 11, 2026 (timely — second business day after the trades).
• Prices reported: $199.00 and $201.10 (F4: $201.10 is a weighted average for sales at $201.00–$201.40; detailed per‑price breakdown available on request).
• Total shares sold: 12,499; Approximate proceeds: $2.5 million.
• Shares owned after the transaction: not stated in the provided excerpt.
• Notable footnotes:
  • F1: Sales executed under a Rule 10b5‑1 trading plan (adopted 12/1/2025).
  • F2, F3, F5: Certain shares are held by trusts/partnerships for which the reporting person disclaims beneficial ownership except for pecuniary interest.
  • F4: Weighted‑average price disclosure for certain lots; reporting person can provide per‑price sales on request.

Context

• Sales executed under a 10b5‑1 plan are pre‑arranged and commonly used for routine liquidity or diversification; they do not necessarily indicate a change in the insider’s view of the company.
• This filing reports only sales — no option exercises, awards, or gifts were disclosed in the provided information.